Furthermore, bFGF, which is a key molecule in myeloid-specific TGF-β signal transduction, can activate the downstream MAPK-ERK-cFOS pathway by binding to FGFR1 to mediate the development of BC bone damage (10). This evidence concerns the gene FGF2 and breast cancer.